MKI67 and glioblastoma: However, the TRPV4 antagonist treatment did not change the percentage of Ki-67-positive cells in intracranial glioblastoma tissues (Fig. S2B), which implied that GSK2 treatment did not affect the proliferation of glioblastoma in vivo.